PIM-1 is a serine-threonine kinase which is mainly expressed in tissues
such as Thymus, spleen, bone marrow, and liver. This protein takes a
role in many stages of the cell cycle, including the regulation of cell
cycle progression and apoptosis. According to many studies,
overexpression of PIM kinases happens in various types of human tumors;
such as lymphomas, prostate cancer, and oral cancer. As a result, the
design of drugs to inhibit PIM-1 in cancerous cells has attracted many
attentions in recent years. This study aimed to design the alternative
inhibitors for PIM-1 kinase, which are based on carbohydrates and amino
acids and are expected to be non-toxic and to have the same
chemotherapeutic effects as the traditional agents. The combinatorial
use of quantum mechanics studies and molecular dynamic simulation (MD)
has enabled us to precisely predict the mechanism of the inhibition of
PIM-1 kinase by the novel designed drugs and to compare them with the
recently synthesized chemotherapeutic drugs; such as DBC.
Inhibition of Cell Cycle Progression by the Novel Cyclophilin Ligand Sanglifehrin A Is Mediated through the NFκB-dependent Activation of p53
